Merck Net Income 2006-2018 | MRK

Merck annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Merck net income for the quarter ending September 30, 2018 was $1.950B, a 3582.14% decline year-over-year.
  • Merck net income for the twelve months ending September 30, 2018 was $3.346B, a 17.53% increase year-over-year.
  • Merck annual net income for 2017 was $2.394B, a 38.93% decline from 2016.
  • Merck annual net income for 2016 was $3.92B, a 11.75% decline from 2015.
  • Merck annual net income for 2015 was $4.442B, a 62.73% decline from 2014.
Merck Annual Net Income
(Millions of US $)
2017 $2,394
2016 $3,920
2015 $4,442
2014 $11,920
2013 $4,404
2012 $6,165
2011 $6,257
2010 $859
2009 $12,853
2008 $7,788
2007 $3,267
2006 $4,434
2005 $4,631
Merck Quarterly Net Income
(Millions of US $)
Q3 2018 $1,950
Q2 2018 $1,707
Q1 2018 $736
Q4 2017 $-1,047
Q3 2017 $-56
Q2 2017 $1,946
Q1 2017 $1,551
Q4 2016 $-594
Q3 2016 $2,184
Q2 2016 $1,205
Q1 2016 $1,125
Q4 2015 $976
Q3 2015 $1,826
Q2 2015 $687
Q1 2015 $953
Q4 2014 $7,316
Q3 2014 $895
Q2 2014 $2,004
Q1 2014 $1,705
Q4 2013 $781
Q3 2013 $1,124
Q2 2013 $906
Q1 2013 $1,593
Q4 2012 $908
Q3 2012 $1,729
Q2 2012 $1,792
Q1 2012 $1,736
Q4 2011 $1,505
Q3 2011 $1,689
Q2 2011 $2,020
Q1 2011 $1,043
Q4 2010 $-534
Q3 2010 $342
Q2 2010 $752
Q1 2010 $299
Q4 2009 $6,447
Q3 2009 $3,424
Q2 2009 $1,556
Q1 2009 $1,425
Q4 2008 $1,624
Q3 2008 $1,093
Q2 2008 $1,768
Q1 2008 $3,303
Q4 2007 $-1,639
Q3 2007 $1,526
Q2 2007 $1,676
Q1 2007 $1,704
Q4 2006 $474
Q3 2006 $941
Q2 2006 $1,499
Q1 2006 $1,520
Q4 2005 $1,120
Q3 2005 $1,421
Q2 2005 $721
Q1 2005 $1,370
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $210.330B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $394.655B 18.50
Pfizer (PFE) United States $262.879B 14.82
Novartis AG (NVS) Switzerland $203.580B 17.45
AbbVie (ABBV) United States $133.274B 11.83
Eli Lilly (LLY) United States $121.123B 21.29
Sanofi (SNY) France $113.240B 14.02
Novo Nordisk (NVO) Denmark $112.427B 18.26
AstraZeneca (AZN) United Kingdom $98.555B 12.24
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $87.225B 14.37